Tell a Friend

  • captcha

Psoriatic Arthritis

Clinical Trial Studies

Currently Recruiting

Protocol

Study Title

Inclusion Summary

M14-496

A phase 4, open-label randomised controlled study, comparing the effectiveness of adalimumab introduction and methotrexate dose escalation in patient’s with Psoriatic Arthritis

Psoriatic arthritis diagnosis for 4 weeks

Active arthritis

First treatment course of methotrexate, duration of 4-36 weeks and dosage ≤15mg weekly

If on oral corticosteroids, < 10mg daily

CAIN 2366

A randomized, double-blind, active control, multicenter study to evaluate the efficacy at week 52 of subcutaneously administered Secukinumab monotherapy compared with subcutaneously administered Adalimumab monotherapy in patients with active psoriatic arthritis

Psoriatic arthritis diagnosis for 6 months

Active Psoriatic arthritis

RF and CCP negative at screening

Active plaque psoriasis

Inadequate control of symptoms with NSAID’s

If on oral corticosteroids, must be on stable dose < 10mg day

Previous cDMARD treatment with inadequate/intolerable response and no Concurrent cDMARD administration

1F-MC-RHCF

A 52-week multicenter, randomized, open-label, parallel-group study, evaluating the efficacy and safety of Ixekizumab versus Adalimumab in patients with psoriatic
arthritis who are biologic disease-modifying anti-rheumatic drug naive

Psoriatic arthritis diagnosis for 6 months

Active Psoriatic arthritis

Active plaque psoriasis

Inadequate response when previously treated with 1 or more csDMARD’s

Upcoming Studies

Protocol

Study Title

Inclusion Summary

M15-554

A phase 3, randomized, double-blind, study comparing ABT-494 to placebo in subjects with active psoriatic arthritis who have a history of inadequate response to at least one biologic disease modifying anti-rheumatic drug (bDMARD)

Psoriatic arthritis diagnosis for 6 months

Active Psoriatic arthritis >3 swollen and tender joints

Active plaque psoriasis, or history of plaque psoriasis

Inadequate response or intolerance to 1 bDMARD

If on oral corticosteroids, stable dose < 10mg daily